用于预防早产的孕激素制剂。

Progestational agents for the prevention of preterm birth.

作者信息

Lamont Ronald F, Jayasooriya Gayani S

机构信息

Northwick Park Institute of Medical Research, London, UK.

出版信息

J Perinat Med. 2009;37(1):12-4. doi: 10.1515/JPM.2009.029.

DOI:10.1515/JPM.2009.029

PMID:18999914

Abstract

Abstract In a risk/benefit analysis, currently the use of PAs used in women with a previous history of PTB appears to be worthwhile though the impact on the PTB rate may be minor since 80-90% of women who deliver preterm have no past history. PTB is a heterogeneous condition. With the exception of extremes of gestational age, PTB is due in equal parts to SPTL, preterm prelabour rupture of the membranes (PPROM) and elective PTB for fetomaternal indications. The assessment of the use of PAs to prevent PTB should only relate to previous and subsequent SPTL and not to PTB due to fetomaternal indications.

摘要

摘要在风险/效益分析中，目前对于有既往早产史的女性使用孕激素似乎是值得的，尽管对早产率的影响可能较小，因为80%至90%的早产女性没有既往史。早产是一种异质性疾病。除了孕周极小的情况外，早产在同等程度上归因于自发性早产、胎膜早破（PPROM）以及因母胎指征而进行的选择性早产。评估孕激素用于预防早产时，应仅涉及既往和后续的自发性早产，而不涉及因母胎指征导致的早产。